Working… Menu

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00385502
Recruitment Status : Completed
First Posted : October 9, 2006
Last Update Posted : September 3, 2020
Information provided by (Responsible Party):
Abeona Therapeutics, Inc

Brief Summary:
Approximately 40 qualified subjects with mild-to-moderate great toenail fungus infection will be treated for 48 weeks with lacquer application to at least one affected great toenail. All subjects will receive treatment with EcoNail™ lacquer.

Condition or disease Intervention/treatment Phase
Onychomycosis Drug: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) Phase 2

Detailed Description:
This study will use a multi-center, open-label study design in subjects with onychomycosis of at least one great toenail to assess the safety, local tolerability, and efficacy of chronic daily ungual application of EcoNail™. Forty (40) evaluable subjects will apply study drug daily to at least one affected great toenail for 48 weeks. The subjects must comply with all inclusion and exclusion criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail
Actual Study Start Date : September 2006
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Molds

Arm Intervention/treatment
Experimental: EcoNail™
econazole 5%/SEPA® 18% nail lacquer
Drug: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
nail lacquer applied daily for 48 weeks
Other Names:
  • econazole
  • SEPA

Primary Outcome Measures :
  1. Determine effectiveness of EcoNail™ lacquer, as determined by effects on nail mycology and appearance, when applied daily for 48 weeks to diseased great toenails in subjects with onychomycosis. [ Time Frame: Week 48 ]

Secondary Outcome Measures :
  1. Evaluate the safety and local tolerability of EcoNail™ lacquer under the same circumstances. [ Time Frame: Week 56 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who are men and women greater than or equal to 18 years of age and less than or equal to 65 years of age.
  • Female subjects who are post-menopausal (amenorrheic for at least 1 year), surgically sterile, have a partner with a vasectomy, or routinely using an acceptable means of contraception (acceptable methods may include hormonal contraceptives, intrauterine device, spermicide and barrier, abstinence and partner/spouse sterility).
  • Subjects who have mycologically confirmed distal subungual onychomycosis of at least one or both great toenails ("target toenails"), defined as a positive result by office-based KOH preparation (± Chlorazol B) and by laboratory culture demonstrating one of more of the following organisms: T. rubrum, T. mentagrophytes, T. tonsurans and/or E. floccosum
  • Subjects who have target toenail showing 20-65% (+/- 2%) involvement as judged by the clinical investigator.
  • Subjects who have target toenail showing great than or equal to 3 mm distal involvement as judged by the clinical investigator.
  • Subjects who have target toenail showing great than or equal to 2 mm proximal clear nail at the cuticle.
  • Subjects must agree not to apply other nail polish or related products to the affected nails for the duration of the study.
  • Subjects must refrain from filing, clipping, or otherwise disturbing the treated nail(s) for the duration of the study [NOTE: Clinic personnel will debride the affected nails during monthly visits. Subjects should not engage in these activities at home during the course of the study.]
  • Subjects must have the ability to understand the nature of the study and any hazards of participating in it and the willingness to communicate satisfactorily with the investigator and staff and to participate in, and comply with the requirements of the entire study.
  • Subjects must be able to read and sign the study Informed Consent form and comply with the requirements outlined in the informed consent form.

Exclusion Criteria:

  • Subjects with < 20% or > 65% (+/- 2%) involvement of the target toenail.
  • Subjects with great than or equal to 4 mm thickness of the target toenail.
  • Subjects with totally dystrophic great toe.
  • Subjects with great toenails which show white superficial or proximal subungual onychomycosis, or a "spike" of onychomycosis extending to the cuticle.
  • Subjects whose nail cultures grow Candida species as the only pathogen.
  • Subjects who have reported treatment with a topical anti-fungal agent for onychomycosis during the four weeks prior to screening for this study.
  • Subjects who have been treated with a systemic anti-fungal agent during the three months prior to screening for this study.
  • Subjects with any other nail abnormality or dermatological condition, including (but not limited to) psoriasis and lichen planus, that could prevent obtaining a normal-appearing toenail if complete cure was achieved or could otherwise interfere with required study assessments.
  • Subjects with a history of organ transplantation, Human Immunodeficiency Virus (HIV) seropositivity or other historical or clinical evidence of an immunocompromised state.
  • Subjects with a history of uncontrolled insulin-dependent diabetes mellitus.
  • Subjects with a history of diabetic peripheral neuropathy.
  • Subjects with a history of clinically significant lower extremity peripheral occlusive vascular disease.
  • Subjects with a presence of plantar (moccasin) tinea pedis.
  • Subjects with a history of hypersensitivity or allergic reactions on the skin or nails, including reactions to nail polish and/or nail polish remover.
  • Subjects known to have an allergy to econazole, ethanol, Eudragit, or SEPA.
  • Female subjects who are pregnant or lactating.
  • Subjects with clinically relevant abnormal history, physical findings, or laboratory values at the screening assessment that could interfere with the objectives or the safety of the volunteer.
  • Subjects who have a condition or abnormality that in the investigator's opinion may interfere with the assessments, conduct of the study, may affect the subject's safety, or is otherwise unsuitable for enrollment.
  • Subjects who are currently participating or, within the previous 30 days, have participated in another investigational drug study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00385502

Layout table for location information
United States, Arizona
Tucson, Arizona, United States, 85741
United States, New York
New York, New York, United States, 10032
United States, Oregon
Portland, Oregon, United States, 97210
Sponsors and Collaborators
Abeona Therapeutics, Inc
Layout table for investigator information
Study Director: Michael H. Silverman, MD Biostrategics Consulting, Ltd.
Additional Information:
Layout table for additonal information
Responsible Party: Abeona Therapeutics, Inc Identifier: NCT00385502    
Other Study ID Numbers: MCHM EC-200
First Posted: October 9, 2006    Key Record Dates
Last Update Posted: September 3, 2020
Last Verified: September 2020
Keywords provided by Abeona Therapeutics, Inc:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Infectious
Nail Diseases
Skin Diseases
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs